Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Stephen Meyer, John Lennox, and James Tour: Three Scientists on the Origins of Everything

Moving from the Big Bang and the discovery of cosmic beginnings, to the fine-tuning of the physical constants that make life possible, to the extraordinary complexity and information embedded in DNA, mathematician John Lennox, philosopher of science Stephen Meyer, and chemist James Tour, explores whether these developments point to blind, undirected processes—or to the activity of an intelligent mind. The trio challenges long-held materialist assumptions, revisits classic scientific debates, and reflects on what these questions mean not only for science but also for our understanding of human existence and purpose.

__________
The opinions expressed are those of the authors and do not necessarily reflect the opinions of the Hoover Institution or Stanford University.

© 2026 by the Board of Trustees of Leland Stanford Junior University.

🔔 Subscribe for more discussions: ‪@HooverInstitution‬
👍 Like and share this video!

🌐 Follow us on social media:
• Facebook: / hooverinststanford.
• LinkedIn: / hoover-institution-at-stanford-university.
• Instagram: / hooverinstitution.
• TikTok: / hooverinstitution.
• X: / hooverinst.

UniQure’s Path for Huntington’s Gene Therapy Clouded by Ethical Questions as Potential Phase 3 Looms

UniQure’s highly promising Huntington’s disease gene therapy BLA (biologics license application) was rejected by the FDA — because UniQure used an external control rather than a surgical sham control. Yet the latter would put control group patients at additional risk, making it ethically problematic. Hopefully some agreement will be reached which circumvents these issues! For now, it is an educational story to watch unfold.

Abi-Saab said during uniQure’s earnings call that he wouldn’t count on the four-year data altering the FDA’s decision.

“We don’t believe that there’s any reason we have today to believe that this will change the FDA’s position regarding the Phase 1/2 trials,” he told investors.

H.C. Wainwright struck a different tone, however, in the Monday note. “While the FDA appears to be enforcing a full sham surgery-controlled Phase 3 trial in Huntington’s, we believe an alternative path forward may be negotiated given the strong AMT-130 data generated to-date,” the analysts wrote. The 4-year data “should further inform the durability and magnitude of effect observed to date.”

Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cells

Now online! Genome-wide CRISPR activation and knockout screens in primary human CD4+ T cells systematically identify host proviral and antiviral factors modulating HIV infection, including the strongly antiviral factor PPID, which is shown to bind HIV capsid and reduce its nuclear import.

Stem cell gene editing to produce B cell protein factories

As a proof of concept, the team used CRISPR gene-editing tools to insert the genetic blueprint for producing rare, protective antibodies directly into hematopoietic stem and progenitor cells of mice. Once transplanted back into mice, the edited stem cells gave rise to B cells programmed to produce the engineered antibody. A conventional vaccination would then serve as the trigger.

It worked. Even when only a few dozen stem cells were edited, vaccination triggered rare cells to expand, mature into plasma cells, and produce large amounts of antibodies that persisted long-term and could be boosted if necessary. The engineered B cells behaved just like normal immune cells, and even provided protection from disease. Mice engineered to produce a broadly neutralizing influenza antibody were spared from an otherwise lethal influenza infection.

The team went on to demonstrate their novel platform’s versatility. Engineered B cells were able to secrete non-antibody proteins, pointing to potential applications in treating genetic diseases caused by missing enzymes or other essential proteins.

The researchers also showed that stem cells carrying different antibody instructions could be combined, enabling a single immune system to produce multiple antibodies at once—an approach that could limit viral escape and ultimately lead to functional cures for rapidly mutating pathogens such as HIV.

And the team showed that human stem cells edited using the same approach gave rise to functional immune cells, providing a key proof of feasibility that the platform could one day work in humans, as well. Science Mission sciencenewshighlights.

An innovative gene-editing strategy could establish a new way for the body to manufacture therapeutic proteins—including certain kinds of highly potent antibodies the are naturally difficult to produce—by reprogramming the immune system itself.

Continue reading “Stem cell gene editing to produce B cell protein factories” | >

Blood test detects aggressive brain tumors early and could reduce need for risky surgery

Researchers at the University of Sussex, in collaboration with scientists from different institutes worldwide, have identified a blood test capable of early diagnosis of the most aggressive form of brain tumor. The technology has the potential to save lives. Lead author Professor Georgios Giamas and his team have identified distinctive biomarkers (molecules that act as signs of normal processes, diseases, or responses to treatment) within patient blood samples, which could signal the presence of glioblastoma, one of the most aggressive forms of brain tumor.

The study published in Cell Reports Medicine investigated whether a simple blood test—analyzing the cargo of tiny particles called small extracellular vesicles (sEVs) that are released by cells into the bloodstream—could accurately detect and classify these tumors.

More than 11,000 people are diagnosed with a primary brain tumor in the U.K. each year. Glioblastoma is the most common high grade primary brain tumor in adults, which means it can grow and spread exceptionally quickly. Currently, diagnosing glioma often requires risky brain surgery.

Primary sclerosing cholangitis

Primary sclerosing cholangitis is a rare, chronic cholestatic liver disease characterised by biliary inflammation and fibrosis. Inflammatory bowel disease co-occurs in 50–80% of individuals with primary sclerosing cholangitis and there is an increased risk for hepatobiliary and colorectal cancers. Primary sclerosing cholangitis presentation is highly variable but there is usually a slowly progressive fibrosis of the bile ducts with strictures, development of liver fibrosis and cirrhosis, and eventually a need for liver transplantation, after which primary sclerosing cholangitis can reoccur.

How Automation and AI Are Transforming Organoid Research

The life sciences are in the midst of a crucial shift, driven by the emergence of organoid-based models and the power of automation. Organoids—three-dimensional cell cultures that mimic human tissue architecture and function—are enabling researchers to ask and answer questions that were once beyond reach. Paired with advances in automation, robotics, and artificial intelligence (AI), these models are transforming drug discovery and preclinical testing, offering a more human-relevant alternative to outdated 2D cell cultures and animal models. This revolution is reshaping the pharmaceutical industry, while also holding the potential to accelerate progress in personalized medicine.

Beyond 2D: The Rise of Organoids

For decades, preclinical research has relied on 2D cell cultures, single-cell-type 3D spheroid models, and animal models, despite their limitations in replicating human biology. Organoids, which are derived from stem cells, offer a more accurate representation of human tissues, recapitulating complex biological processes such as organ-specific functionality and cellular interactions. These miniature self-organizing biological systems are being used to model diseases, test drug efficacy and toxicity, and even explore regenerative medicine.

Single mathematical model helps solve a decades-old puzzle involving ultrafast lasers

A team of international researchers, including an Aston University researcher, has cracked the code on how “breather” laser pulses work, creating a single mathematical model that explains two completely different laser behaviors for the first time. Ultrafast lasers emit extremely short pulses of light, lasting only picoseconds or femtoseconds, making them essential for applications ranging from eye surgery and biomedical imaging to precision materials processing and advanced manufacturing.

The work is published in the journal Physical Review Letters. By understanding laser behaviors better, scientists will be able to control them, making lasers more reliable and better suited to specific applications.

An ultrafast laser produces pulses of light that circulate within the laser cavity, where they can evolve into stable structures called solitons. Solitons tend to maintain their shape as they travel, unlike conventional light pulses which spread out. Usually, these solitons are identical and regular, like a heartbeat, known as steady-state emission. In a “breather” laser, the solitons change over time and successive cavity round trips, growing and shrinking before repeating the cycle, like a breathing pattern. This is an example of a non-equilibrium state, where the laser output does not remain constant but keeps evolving over time.

Each protein in the epigenome produces a different pattern of gene expression, study finds

A new study finds the proteins responsible for controlling which genes are expressed in a genome do more than simply turn a gene on or off. Essentially, each type of protein that interacts with a gene produces different behaviors—a finding with ramifications for everything from biomedical therapeutics to biological computing. A paper on the study, “Epigenome Regulators Imbue a Single Eukaryotic Promoter with Diverse Gene Expression Dynamics,” is published in the journal iScience.

At issue are “epigenome regulators.” Every organism’s genome is made up of DNA. But that DNA is bound up with many different proteins into very compact structures. The proteins that are bound to the DNA are called the epigenome, and they control which parts of the DNA get expressed. Your blood cells, nerve cells, and skin cells all have the same DNA, but perform very different functions. That’s because different parts of the DNA sequence are being expressed in each cell—and that is largely controlled by which proteins are bound to different parts of the DNA in each cell.

“We already knew that the proteins in the epigenome control the way DNA is expressed,” says Albert Keung, corresponding author of the study and an associate professor of chemical and biomolecular engineering at North Carolina State University. “Our goal here was to look at a single gene and quantify the full range of ways that the gene could be expressed by different proteins.” Keung is the Goodnight Distinguished Scholar in Innovation in Biotechnology and Biomolecular Engineering and director of biotechnology programs in NC State’s Integrative Sciences Initiative.

AI model ‘reads’ protein pairs, unlocking new insights into disease and drug discovery

Researchers have developed a new artificial intelligence (AI) model that can more accurately predict how proteins interact with one another—an advancement that could accelerate drug discovery and deepen insights into diseases such as cancer.

Led by Professor Zhang Yang, Senior Principal Investigator from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, and published in Nature Communications, the study introduces a paired protein language model (PPLM) that learns from two interacting proteins simultaneously, rather than analyzing them in isolation. This marks a significant shift in how AI is applied to biology, enabling more accurate prediction of protein–protein interactions that underpin nearly all cellular processes.

/* */